Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728728 · ClinicalTrials.gov registry record · Phase 2
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00728728: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT00728728 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00728728, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
Primary Outcome
The MATRICS Consensus Cognitive Battery (MCCB) is a standardized battery for use with adults with schizophrenia and related disorders to measure cognition in these individuals. The MCCB consists of ten individually administered test which measure speed of processing, attention/vigilance, nonverbal working memory, verbal working memory, verbal learning, visual learning, reasoning and problem solving and social cognition. The primary raw scores are entered into the MCCB Computer Scoring Program w
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Dietary Supplement: Pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT00728728 record still lists
NCT00728728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00728728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00728728 about?
NCT00728728 is a clinical study titled "Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia". This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
What is the current status of trial NCT00728728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2009-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00728728?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Dietary Supplement: Pregnenolone (DRUG).
Who is sponsoring clinical trial NCT00728728?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00728728's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia